A Trial of Early Percutaneous Catheter Drainage of Sterile Pancreatic Fluid Collections in Severe Acute Pancreatitis
EPCDSAP
A Randomized, Multicenter and Prospective Trial of Early Percutaneous Catheter Drainage of Sterile Pancreatic Fluid Collections in Severe Acute Pancreatitis
1 other identifier
interventional
100
1 country
1
Brief Summary
The acute peripancreatic fluid collections (AFPCs) is the most common complication in severe acute pancreatitis (SAP). There are controversies on optimal timing for drainage of APFCs in SAP. The early-stage percutaneous catheter drainage (PCD) of sterile peripancreatic fluid collections is questioned as a result of the major cause of secondary infection. The aim of the present randomized controlled trial is to compare the outcomes in terms of mortality, secondary infection of peripancreatic collections, organ failure, length of hospital/ICU stay and inflammatory biomarkers between the early-stage PCD of sterile AFPCs and conservative therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2017
CompletedFirst Posted
Study publicly available on registry
June 14, 2017
CompletedStudy Start
First participant enrolled
October 6, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 6, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 6, 2020
CompletedOctober 9, 2017
May 1, 2017
3 years
May 30, 2017
October 5, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
Determine and compare the death rates in patients who are administered drainage and conservative therapy: Assess the total number of cases of death in each group (Treatment and control)
From date of admisstion until the date of in-hospital death or death within two weeks after discharging, whichever came first, assessed up to 1 year.
Secondary Outcomes (6)
Secondary infection of peripancreatic collections
From date of admisstion until the secondary infection of peripancreatic collections occurred, assessed up to 100 days
New set of organ failure
From date of admisstion until new set of organ failure occurred, assessed up to 100 days
Length of hospital/ICU stay
From date of admisstion until the patient is transfered to normal ward or discharge, whichever came first, assessed up to 1 year.
Aggressive procedures: open necrosectomy and minimally invasive retroperitoneal necrosectomy
From date of admisstion until the patient receives aggressive procedures, assessed up to 100 days
Abdominal hemorrhage
From date of admisstion until the abdominal hemorrhage occurred, assessed up to 100 days
- +1 more secondary outcomes
Study Arms (2)
Puncture and Drainage
EXPERIMENTALThe enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
Conservative therapy
NO INTERVENTIONThe enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
Interventions
The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
Eligibility Criteria
You may qualify if:
- Age of 18 years to 70 years; and
- Pain characteristic of pancreatitis; and
- Elevated serum lipase or amylase (≥3-fold upper normal range); and
- Persistent organ failure \>48 hours; and
- Organ dysfunction occurred within 7 days after onset of pain; and
- Presentation with a width of ≥2cm of APFCs in the peripheral tissues of the pancreas, the cyst of lesser omentum , or the paracolic sulci on CT image.
You may not qualify if:
- History diseases of chronic organ dysfunction; or
- Traumatic pancreatitis; or
- Post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis; or
- Severe coagulopathy (INR\>2); or
- Severe thrombocytopenia (PLT≤50×109/L); or
- No suitable route for puncturing; or
- Pregnancy; or
- Absent of informed consent from patient or representative.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The second affiliated hospital of Zhejiang University
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2017
First Posted
June 14, 2017
Study Start
October 6, 2017
Primary Completion
October 6, 2020
Study Completion
October 6, 2020
Last Updated
October 9, 2017
Record last verified: 2017-05